Odonate Therapeutics Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Odonate Therapeutics's estimated annual revenue is currently $9.3M per year.
- Odonate Therapeutics's estimated revenue per employee is $72,656
- Odonate Therapeutics has 128 Employees.
- Odonate Therapeutics grew their employee count by 5% last year.
- Odonate Therapeutics currently has 3 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
|Advanced Cell D...||$28.7M||185||8%||N/A||-||N/A|
|The J. Craig Ve...||$39.4M||254||N/A||N/A||-||N/A|
What Is Odonate Therapeutics?
Odonate Therapeutics is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.keywords:N/A
Number of Employees
Employee Growth %
Odonate Therapeutics News
Shares of Odonate Therapeutics, Inc. (:ODT) have been on a recent steady downtrend, causing some worry for shareholders. Investors may be ...
Shares of Odonate Therapeutics, Inc. (ODT) have been trending lower over the past five bars, revealing bearish momentum for the shares, ...
Carillon Tower Advisers Inc. purchased a new stake in shares of Odonate Therapeutics Inc (NASDAQ:ODT) during the 2nd quarter, according ...